Positive Results on First Pacemaker Designed for Use with MRI
|
By MedImaging International staff writers Posted on 18 Jun 2009 |
A new study confirmed that a pacing system could help cardiac device patients benefit from the use of magnetic resonance imaging (MRI). Currently, due to safety considerations, there are no implantable pacemakers or defibrillators approved for use with MRI in the United States.
New data announced at Heart Rhythm 2009, the annual congress of the Heart Rhythm Society, demonstrated that patients implanted with the investigational EnRhythm MRI SureScan pacing system, developed by Medtronic, Inc. (Minneapolis, MN, USA), experienced no complications related to the use of MRI. Commercially released in Europe, the EnRhythm MRI SureScan system is the world's first pacing system designed and approved for use with MRI.
Patients with currently implanted pacemaker and defibrillator systems are strongly discouraged from receiving an MRI scan, according to medical guidelines and the U.S. Food and Drug Administration (FDA). Studies have shown that commonly used MRI scanners can interrupt or withhold pacing therapy, deliver unnecessary pacing therapy that may be hazardous and possibly life-threatening, and/or cause damage to the device, regardless of which company manufactured the device.
"Each year, approximately one million people are implanted with a pacemaker, thousands of whom should receive diagnostic MRI scans,” said Bruce L. Wilkoff, M.D., director of cardiac pacing and tachyarrhythmia devices, department of cardiovascular medicine and professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (Cleveland, OH, USA). "This investigational study showed positive results, indicating that many more patients may have access to MRI, a vital and often irreplaceable tool in detecting and managing conditions such as cancer and neurological disorders.” (Dr. Wilkoff is a paid consultant assisting Medtronic in the development of this therapy.)
Results showed that Medtronic's investigational EnRhythm MRI SureScan pacing system still performs as intended during and after an MRI when used according to the product's labeling. The data showed no MRI-related complications, and no arrhythmias, or asystole (absence of electrical activity in the heart) during MRI scans.
"Despite well-documented risks and warnings of MRI-related complications, pacemaker patients do receive MRI scans off label,” said David Steinhaus, M.D., medical director of the cardiac rhythm disease management business at Medtronic. "Physicians and patients faced with urgent clinical needs have had to make difficult risk/benefit decisions and accept the risks of an MRI scan. Through our development process, we identified real risks and designed a system to address these risks for pacemaker patients. We are encouraged by the clinical results of the EnRhythm MRI SureScan pacing system, as we believe that providing safe access to MRI for pacemaker patients can reduce risk and lead to better health outcomes.”
This prospective, randomized, controlled trial involved 464 individuals successfully implanted at 41 centers in the United States, Canada, Europe, and the Middle East. After successful implant of pacemaker and leads, 258 patients were randomized to MRI and 206 to no MRI (control). All patients were evaluated before and after the scan, and one week and one month after MRI scan/control visit. There was no difference in performance between the MRI group and the control group.
Related Links:
Medtronic
New data announced at Heart Rhythm 2009, the annual congress of the Heart Rhythm Society, demonstrated that patients implanted with the investigational EnRhythm MRI SureScan pacing system, developed by Medtronic, Inc. (Minneapolis, MN, USA), experienced no complications related to the use of MRI. Commercially released in Europe, the EnRhythm MRI SureScan system is the world's first pacing system designed and approved for use with MRI.
Patients with currently implanted pacemaker and defibrillator systems are strongly discouraged from receiving an MRI scan, according to medical guidelines and the U.S. Food and Drug Administration (FDA). Studies have shown that commonly used MRI scanners can interrupt or withhold pacing therapy, deliver unnecessary pacing therapy that may be hazardous and possibly life-threatening, and/or cause damage to the device, regardless of which company manufactured the device.
"Each year, approximately one million people are implanted with a pacemaker, thousands of whom should receive diagnostic MRI scans,” said Bruce L. Wilkoff, M.D., director of cardiac pacing and tachyarrhythmia devices, department of cardiovascular medicine and professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (Cleveland, OH, USA). "This investigational study showed positive results, indicating that many more patients may have access to MRI, a vital and often irreplaceable tool in detecting and managing conditions such as cancer and neurological disorders.” (Dr. Wilkoff is a paid consultant assisting Medtronic in the development of this therapy.)
Results showed that Medtronic's investigational EnRhythm MRI SureScan pacing system still performs as intended during and after an MRI when used according to the product's labeling. The data showed no MRI-related complications, and no arrhythmias, or asystole (absence of electrical activity in the heart) during MRI scans.
"Despite well-documented risks and warnings of MRI-related complications, pacemaker patients do receive MRI scans off label,” said David Steinhaus, M.D., medical director of the cardiac rhythm disease management business at Medtronic. "Physicians and patients faced with urgent clinical needs have had to make difficult risk/benefit decisions and accept the risks of an MRI scan. Through our development process, we identified real risks and designed a system to address these risks for pacemaker patients. We are encouraged by the clinical results of the EnRhythm MRI SureScan pacing system, as we believe that providing safe access to MRI for pacemaker patients can reduce risk and lead to better health outcomes.”
This prospective, randomized, controlled trial involved 464 individuals successfully implanted at 41 centers in the United States, Canada, Europe, and the Middle East. After successful implant of pacemaker and leads, 258 patients were randomized to MRI and 206 to no MRI (control). All patients were evaluated before and after the scan, and one week and one month after MRI scan/control visit. There was no difference in performance between the MRI group and the control group.
Related Links:
Medtronic
Latest MRI News
- AI Approach Could Shorten Advanced Brain MRI Scans by Up to 90%
- Cardiac MRI Measure Improves Risk Prediction in Tricuspid Regurgitation
- AI System Improves Accuracy of Cardiac MRI Interpretation
- Deep Learning Model Predicts Alzheimer’s Disease Outcomes from Baseline MRI
- Blood-Brain Barrier Imaging Adds Risk Insight to Standard Stroke MRI
- AI Body Composition MRI Analysis Predicts Cardiometabolic Disease Risk
- AI MRI Tool Quantifies Muscle Fat to Assess Cardiometabolic Risk
- Advanced MRI Visualizes CSF Motion Changes After Mild Traumatic Brain Injury
- MRI Tool Enables Long-Term Tracking of Transplanted Cardiac Cells
- MRI-Based AI Tool Supports Differentiation of Parkinsonian Syndromes
- MRI-Derived Biomarker Improves Risk Stratification in Glioblastoma
- Combined Imaging Approach Identifies Cause of Heart Attack without Coronary Blockage
- Advanced MRI System Detects Impaired Cardiac Oxygen Use in Minutes
- AI-Enhanced MRI Improves Image Quality in Arrhythmia Patients
- Ultra-Detailed Brain Atlas Enhances Early Detection of Neurological Disorders
- Study Finds Advanced Imaging Significantly Reduces Unnecessary Prostate Biopsies
Channels
Radiography
view channel
Rapid X-Ray Test Quantifies Pulmonary Regurgitation After Tetralogy of Fallot Repair
Tetralogy of Fallot is the most common cyanotic congenital heart defect and can leave patients with pulmonary valve regurgitation, a backward flow of blood into the right ventricle after repair.... Read more
AI Tool Flags Osteoporosis Risk from Routine Chest X-Rays
Osteoporosis is a progressive loss of bone density that is often silent until a fracture occurs. Current screening frameworks concentrate on older women and select high-risk groups. Many men, younger adults,... Read moreUltrasound
view channelAI Robotic Ultrasound System Automates Echocardiography and Improves Consistency
Echocardiography, an ultrasound examination of the heart, is central to diagnosing and managing cardiovascular disease. Many services struggle with limited availability of skilled sonographers, variable... Read more
Whole Cross-Section Ultrasound System Enables Operator-Independent Imaging
Conventional ultrasound is central to bedside imaging but is limited by a narrow field of view and operator variability. Comprehensive cross-sectional assessment typically requires computed tomography... Read moreNuclear Medicine
view channel
Targeted PET Platform Guides Osteosarcoma Resection and Margin Verification
Osteosarcoma, an aggressive primary bone cancer that mainly affects children and adolescents, demands wide excision to prevent local recurrence. Surgeons must achieve negative margins while preserving... Read more
Portable PET System Enables Real-Time Bedside Guidance for Biopsies and Ablations
Interventional radiology procedures typically rely on ultrasound, X-ray fluoroscopy, or computed tomography for image guidance. These modalities visualize anatomy but offer limited molecular information,... Read moreGeneral/Advanced Imaging
view channelNew SPECT/CT Method Differentiates Inflammation from Fibrosis in Interstitial Lung Disease
Interstitial lung disease (ILD) encompasses more than 200 disorders that inflame or scar the lung interstitium and can lead to progressive respiratory failure. Determining whether active inflammation is... Read more
Whole-Body PET/CT Tracks Metabolic Changes After Bariatric Surgery
Obesity surgery improves weight and comorbidity profiles, yet clinicians lack tools to monitor organ-level metabolic recovery after the procedure. A clear view of systemic changes could refine follow-up... Read moreImaging IT
view channel
Interactive AI Tool Supports Explainable Lung Nodule Assessment
Lung cancer is a leading cause of cancer mortality, and timely characterization of pulmonary nodules on chest computed tomography (CT) is essential for directing care. Interpreting nodule morphology demands... Read more
Breast Imaging Software Enhances Visualization and Tissue Characterization in Challenging Cases
Breast imaging can be particularly challenging in cases involving small breasts or implants, where image reconstruction and tissue characterization may be limited. Clinicians also need reproducible analysis... Read more
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology
The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read moreIndustry News
view channel
GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026
Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
GE HealthCare Highlights AI-Supported Radiation Therapy Tools at ESTRO 2026
At the European Society for Radiotherapy and Oncology (ESTRO) 2026 Congress in Stockholm, GE HealthCare is highlighting Intelligent Radiation Therapy (iRT), MIM Software innovations, and BK Medical surgical... Read more







